ClinicalTrials.gg

Program

Nifedipine

Also written as “Nifedipine (Adalat, BAYA1040)”, “Adalat (Nifedipine, BAYA1040)” and “Nifedipine Extended Release tablets 60 mg, single dose”.

Its studies are mostly in Hypertension · Essential Hypertension · Fissure in Ano · Diabetic Nephropathies, led by 4 companies.

Furthest: phase 4, since Apr 16, 200817 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bayer120 open or runningphase 4since Apr 16, 2008Apr 16, 2008none ahead
RDD Pharma20 open or runningphase 3since Aug 10, 2015Dec 11, 2013none ahead
Teva Pharmaceutical Industries20 open or runningphase 1since Mar 18, 2009Mar 18, 2009none ahead
Reig Jofre Group10 open or runningphase 1since Dec 3, 2013Dec 3, 2013none ahead

Also a collaborator on its studies: laboratorios-richmond-colombia-sas.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 2 studies since Apr 16, 2008.

  1. Sep 9, 2008Phase 4 study in HypertensionBayer · NCT00750113 · 405 enrolled · Italy, Spain
  2. Oct 7, 2008Phase 2 study in HypertensionBayer · NCT00768560 · 35 enrolled · Japan
  3. Mar 18, 2009Teva Pharmaceutical Industries's first studies: 2 phase 1 studies in HealthyNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT00865891, NCT00864617
  4. Oct 9, 2009Phase 4 study in HypertensionBayer · NCT00993109 · 360 enrolled · China, Korea, Republic of
  5. Feb 18, 2010Phase 4 study in HypertensionBayer · NCT01071122 · 365 enrolled · Korea, Republic of
  6. Jan 30, 2011Phase 3 study in HypertensionBayer · NCT01287260 · 352 enrolled · Japan
  7. Feb 10, 2011Phase 3 study in HypertensionBayer · NCT01294215 · 72 enrolled · Japan
  8. Apr 18, 2011Phase 1 study in Essential HypertensionBayer · NCT01350609 · 49 enrolled · Germany
  9. Apr 21, 2011Phase 3 study in HypertensionBayer · NCT01355367 · 120 enrolled · Japan
  10. Jan 24, 2012Phase 4 study in HypertensionBayer · NCT01518855 · 514 enrolled · Japan
  11. Dec 3, 2013Reig Jofre Group's first study: phase 1 study in BioequivalenceNew to Reig Jofre GroupReig Jofre Group · NCT02071589 · 36 enrolled · Spain
  12. Dec 11, 2013RDD Pharma's first study: phase 2 study in Fissure in AnoNew to RDD PharmaRDD Pharma · NCT02023047 · 33 enrolled · Israel
  13. Apr 2, 2015Phase 4 study in HypertensionBayer · NCT02413515 · 278 enrolled · China
  14. Aug 10, 2015Phase 3 study in Chronic Anal FissureRDD Pharma · NCT02527109 · 339 enrolled · Bulgaria, Moldova, Republic of, Poland and more

TargetBeta

“Voltage-gated L-type calcium channel blocker”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
AmlodipineruleNovartisphase 4203
PregabalinruleViatrisphase 4149
GabapentinruleViatrisphase 449
DronedaroneruleSanofiphase 418

Studies

All 17 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT02527109Chronic Anal Fissure · Bulgaria, Moldova, Republic of, Poland and more3CompletedRDD PharmaJun 15, 2018339
NCT02413515Hypertension · China4CompletedBayerAug 8, 2016278
NCT02023047Fissure in Ano · Israel2TerminatedRDD PharmaNov 201533
NCT02071589Bioequivalence · Spain1CompletedReig Jofre GroupMar 200936
NCT01518855Hypertension · Japan4CompletedBayerApr 2005514
NCT01355367Hypertension · Japan3CompletedBayerSep 2011120
NCT01350609Essential Hypertension · Germany1CompletedBayerAug 201149
NCT01294215Hypertension · Japan3CompletedBayerNov 201172
NCT01287260Hypertension · Japan3CompletedBayerAug 2011352
NCT01071122Hypertension · Korea, Republic of4CompletedBayerFeb 2012365
NCT00993109Hypertension · China, Korea, Republic of4CompletedBayerMay 2011360
NCT00865891Healthy · United States1CompletedTeva Pharmaceutical IndustriesJul 200596
NCT00864617Healthy · United States1CompletedTeva Pharmaceutical IndustriesMay 200584
NCT00768560Hypertension · Japan2CompletedBayerMay 200835
NCT00750113Hypertension · Italy, Spain4CompletedBayerJul 2009405
NCT00713011Diabetic Nephropathies3WithdrawnBayerMar 20090
NCT00672113Hypertension · United Kingdom4CompletedBayer43

How it is read

Names in the registry

  • “Nifedipine (Adalat, BAYA1040)”, 6 entries
  • “Adalat (Nifedipine, BAYA1040)”, 2 entries
  • “Nifedipine Extended Release tablets 60 mg, single dose”, 2 entries
  • “Treatment with Nifedipine 30 mg Extended-Release (Richmond)”, 1 entry
  • “Nifedipine”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.